APL 1301

Drug Profile

APL 1301

Alternative Names: APL-1301

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asieris Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Urogenital cancer

Most Recent Events

  • 29 Aug 2017 APL 1301 is available for licensing as of 29 Aug 2017. http://www.asieris.cn/index/
  • 29 Aug 2017 Phase-I clinical trials in Urogenital cancer in China (PO) (Asieris Pharmaceuticals website, August 2017)
  • 29 Aug 2017 Asieris Pharmaceuticals plans to submit a US IND application for Urogenital cancers, in late 2017 or early 2018 (Asieris Pharmaceuticals website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top